<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34796871</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2050-084X</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><PubDate><Year>2021</Year><Month>Nov</Month><Day>19</Day></PubDate></JournalIssue><Title>eLife</Title><ISOAbbreviation>Elife</ISOAbbreviation></Journal><ArticleTitle>Enrichment of <i>SARM1</i> alleles encoding variants with constitutively hyperactive NADase in patients with ALS and other motor nerve disorders.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e70905</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7554/eLife.70905</ELocationID><Abstract><AbstractText>SARM1, a protein with critical NADase activity, is a central executioner in a conserved programme of axon degeneration. We report seven rare missense or in-frame microdeletion human <i>SARM1</i> variant alleles in patients with amyotrophic lateral sclerosis (ALS) or other motor nerve disorders that alter the SARM1 auto-inhibitory ARM domain and constitutively hyperactivate SARM1 NADase activity. The constitutive NADase activity of these seven variants is similar to that of SARM1 lacking the entire ARM domain and greatly exceeds the activity of wild-type SARM1, even in the presence of nicotinamide mononucleotide (NMN), its physiological activator. This rise in constitutive activity alone is enough to promote neuronal degeneration in response to otherwise non-harmful, mild stress. Importantly, these strong gain-of-function alleles are completely patient-specific in the cohorts studied and show a highly significant association with disease at the single gene level. These findings of disease-associated coding variants that alter SARM1 function build on previously reported genome-wide significant association with ALS for a neighbouring, more common <i>SARM1</i> intragenic single nucleotide polymorphism (SNP) to support a contributory role of SARM1 in these disorders. A broad phenotypic heterogeneity and variable age-of-onset of disease among patients with these alleles also raises intriguing questions about the pathogenic mechanism of hyperactive SARM1 variants.</AbstractText><CopyrightInformation>&#xa9; 2021, Gilley et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gilley</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9510-7956</Identifier><AffiliationInfo><Affiliation>John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-1825-9331</Identifier><AffiliationInfo><Affiliation>John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pipis</LastName><ForeName>Menelaos</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuromuscular Disease, UCL Queen Square Institute of Neurology and The National Hospital for Neurology, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estiar</LastName><ForeName>Mehrdad A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, King's College Hospital, King's College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danzi</LastName><ForeName>Matt C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Dr. John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Eijk</LastName><ForeName>Kristel R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goutman</LastName><ForeName>Stephen A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harms</LastName><ForeName>Matthew B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Institute for Genomic Medicine, Columbia University, New York, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houlden</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neuromuscular Disease, UCL Queen Square Institute of Neurology and The National Hospital for Neurology, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iacoangeli</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research Biomedical Research Centre and Dementia Unit at South London and Maudsley NHS Foundation Trust and King's College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaye</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Systems and Therapeutics, Gladstone Institutes, San Francisco, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lima</LastName><ForeName>Leandro</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Systems and Therapeutics, Gladstone Institutes, San Francisco, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gladstone Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Queen Square Genomics</CollectiveName><AffiliationInfo><Affiliation>Department of Neuromuscular Disease, UCL Queen Square Institute of Neurology and The National Hospital for Neurology, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravits</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rouleau</LastName><ForeName>Guy A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xfc;le</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Neurology and Hertie Institute f&#xfc;r Clinical Brain Research, University of T&#xfc;bingen, German Center for Neurodegenerative Diseases, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jishu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Neurology and Hertie Institute f&#xfc;r Clinical Brain Research, University of T&#xfc;bingen, German Center for Neurodegenerative Diseases, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Z&#xfc;chner</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dr. John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper-Knock</LastName><ForeName>Johnathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan-Or</LastName><ForeName>Ziv</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reilly</LastName><ForeName>Mary M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Neuromuscular Disease, UCL Queen Square Institute of Neurology and The National Hospital for Neurology, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coleman</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/L501529/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>220906/Z/20/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U54 NS065712</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54NS065712</GrantID><Agency>National Institutes of Neurological Diseases and Stroke and office of Rare Diseases</Agency><Country/></Grant><Grant><GrantID>MR/R024804/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 NS072248</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 ES027221</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>216596/Z/19/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 NS105755</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>BB/S009582/1</GrantID><Acronym>BB_</Acronym><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/N004582/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Elife</MedlineTA><NlmUniqueID>101579614</NlmUniqueID><ISSNLinking>2050-084X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051186">Armadillo Domain Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003598">Cytoskeletal Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C435689">SARM1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>1094-61-7</RegistryNumber><NameOfSubstance UI="D009537">Nicotinamide Mononucleotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.2.5</RegistryNumber><NameOfSubstance UI="D009244">NAD+ Nucleosidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051186" MajorTopicYN="N">Armadillo Domain Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003598" MajorTopicYN="N">Cytoskeletal Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="N">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009244" MajorTopicYN="N">NAD+ Nucleosidase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009537" MajorTopicYN="N">Nicotinamide Mononucleotide</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">NADase</Keyword><Keyword MajorTopicYN="N">SARM1</Keyword><Keyword MajorTopicYN="N">genetics</Keyword><Keyword MajorTopicYN="N">genomics</Keyword><Keyword MajorTopicYN="N">human</Keyword><Keyword MajorTopicYN="N">neuroscience</Keyword><Keyword MajorTopicYN="N">risk allele</Keyword></KeywordList><CoiStatement>JG Part-funded by AstraZeneca during the past 3 years, OJ Currently part-funded by AstraZeneca, MP, ME, AA, MD, Kv, SG, MH, HH, AI, JK, LL, JR, GR, RS, JX, SZ, JC, ZG, MR No competing interests declared, MC Consults for Nura Bio, but no support provided for this work</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>19</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34796871</ArticleId><ArticleId IdType="pmc">PMC8735862</ArticleId><ArticleId IdType="doi">10.7554/eLife.70905</ArticleId><ArticleId IdType="pii">70905</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Angeletti C, Amici A, Gilley J, Loreto A, Trapanotto AG, Antoniou C, Coleman MP, Orsomando G. Programmed Axon Death Executor SARM1 Is a Multi-Functional NAD(P)Ase with Prominent Base Exchange Activity, All Regulated by Physiological Levels of NMN, NAD, NADP and Other Metabolites. bioRxiv. 2021 doi: 10.1101/2021.07.14.451805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.14.451805</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochemical and Biophysical Research Communications. 2006;351:602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom AJ, Mao X, Strickland A, Sasaki Y, Milbrandt J, DiAntonio A. Constitutively active SARM1 variants found in ALS patients induce neuropathy. bioRxiv. 2021 doi: 10.1101/2021.04.16.439886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.16.439886</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosanac T, Hughes RO, Engber T, Devraj R, Brearley A, Danker K, Young K, Kopatz J, Hermann M, Berthemy A, Boyce S, Bentley J, Krauss R. Pharmacological SARM1 inhibition protects axon structure and function in paclitaxel-induced peripheral neuropathy. Brain: A Journal of Neurology. 2021;8:awab184. doi: 10.1093/brain/awab184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab184</ArticleId><ArticleId IdType="pmc">PMC8634121</ArticleId><ArticleId IdType="pubmed">33964142</ArticleId></ArticleIdList></Reference><Reference><Citation>Bratkowski M, Xie T, Thayer DA, Lad S, Mathur P, Yang YS, Danko G, Burdett TC, Danao J, Cantor A, Kozak JA, Brown SP, Bai X, Sambashivan S. Structural and Mechanistic Regulation of the Pro-degenerative NAD Hydrolase SARM1. Cell Reports. 2020;32:107999. doi: 10.1016/j.celrep.2020.107999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.107999</ArticleId><ArticleId IdType="pubmed">32755591</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CY, Lin CW, Chang CY, Jiang ST, Hsueh YP. Sarm1, a negative regulator of innate immunity, interacts with syndecan-2 and regulates neuronal morphology. The Journal of Cell Biology. 2011;193:769&#x2013;784. doi: 10.1083/jcb.201008050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201008050</ArticleId><ArticleId IdType="pmc">PMC3166868</ArticleId><ArticleId IdType="pubmed">21555464</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman MP, H&#xf6;ke A. Programmed axon degeneration: from mouse to mechanism to medicine. Nature Reviews. Neuroscience. 2020;21:183&#x2013;196. doi: 10.1038/s41583-020-0269-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-020-0269-3</ArticleId><ArticleId IdType="pubmed">32152523</ArticleId></ArticleIdList></Reference><Reference><Citation>Conforti L, Gilley J, Coleman MP. Wallerian degeneration: an emerging axon death pathway linking injury and disease. Nature Reviews. Neuroscience. 2014;15:394&#x2013;409. doi: 10.1038/nrn3680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3680</ArticleId><ArticleId IdType="pubmed">24840802</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies RB. Algorithm AS 155: The Distribution of a Linear Combination of &#x3c7; 2 Random Variables. Applied Statistics. 1980;29:323. doi: 10.2307/2346911.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2346911</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stefano M, Nascimento-Ferreira I, Orsomando G, Mori V, Gilley J, Brown R, Janeckova L, Vargas ME, Worrell LA, Loreto A, Tickle J, Patrick J, Webster JRM, Marangoni M, Carpi FM, Pucciarelli S, Rossi F, Meng W, Sagasti A, Ribchester RR, Magni G, Coleman MP, Conforti L. A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration. Cell Death and Differentiation. 2015;22:731&#x2013;742. doi: 10.1038/cdd.2014.164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2014.164</ArticleId><ArticleId IdType="pmc">PMC4392071</ArticleId><ArticleId IdType="pubmed">25323584</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stefano M, Loreto A, Orsomando G, Mori V, Zamporlini F, Hulse RP, Webster J, Donaldson LF, Gering M, Raffaelli N, Coleman MP, Gilley J, Conforti L. NMN deamidase delays wallerian degeneration and rescues axonal defects caused by NMNAT2 deficiency in vivo. Current Biology. 2017;27:784&#x2013;794. doi: 10.1016/j.cub.2017.01.070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2017.01.070</ArticleId><ArticleId IdType="pubmed">28262487</ArticleId></ArticleIdList></Reference><Reference><Citation>Essuman K, Summers DW, Sasaki Y, Mao X, DiAntonio A, Milbrandt J. The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration. Neuron. 2017;93:1334&#x2013;1343. doi: 10.1016/j.neuron.2017.02.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.02.022</ArticleId><ArticleId IdType="pmc">PMC6284238</ArticleId><ArticleId IdType="pubmed">28334607</ArticleId></ArticleIdList></Reference><Reference><Citation>Essuman K, Summers DW, Sasaki Y, Mao X, Yim AKY, DiAntonio A, Milbrandt J. TIR Domain Proteins Are an Ancient Family of NAD+-Consuming Enzymes. Current Biology. 2018;28:421&#x2013;430. doi: 10.1016/j.cub.2017.12.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2017.12.024</ArticleId><ArticleId IdType="pmc">PMC5802418</ArticleId><ArticleId IdType="pubmed">29395922</ArticleId></ArticleIdList></Reference><Reference><Citation>Figley MD, DiAntonio A. The SARM1 axon degeneration pathway: control of the NAD+ metabolome regulates axon survival in health and disease. Current Opinion in Neurobiology. 2020;63:59&#x2013;66. doi: 10.1016/j.conb.2020.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2020.02.012</ArticleId><ArticleId IdType="pmc">PMC7483800</ArticleId><ArticleId IdType="pubmed">32311648</ArticleId></ArticleIdList></Reference><Reference><Citation>Figley MD, Gu W, Nanson JD, Shi Y, Sasaki Y, Cunnea K, Malde AK, Jia X, Luo Z, Saikot FK, Mosaiab T, Masic V, Holt S, Hartley-Tassell L, McGuinness HY, Manik MK, Bosanac T, Landsberg MJ, Kerry PS, Mobli M, Hughes RO, Milbrandt J, Kobe B, DiAntonio A, Ve T. SARM1 is a metabolic sensor activated by an increased NMN/NAD+ ratio to trigger axon degeneration. Neuron. 2021;109:1118&#x2013;1136. doi: 10.1016/j.neuron.2021.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2021.02.009</ArticleId><ArticleId IdType="pmc">PMC8174188</ArticleId><ArticleId IdType="pubmed">33657413</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogh I, Ratti A, Gellera C, Lin K, Tiloca C, Moskvina V, Corrado L, Sorar&#xf9; G, Cereda C, Corti S, Gentilini D, Calini D, Castellotti B, Mazzini L, Querin G, Gagliardi S, Del Bo R, Conforti FL, Siciliano G, Inghilleri M, Sacc&#xe0; F, Bongioanni P, Penco S, Corbo M, Sorbi S, Filosto M, Ferlini A, Di Blasio AM, Signorini S, Shatunov A, Jones A, Shaw PJ, Morrison KE, Farmer AE, Van Damme P, Robberecht W, Chi&#xf2; A, Traynor BJ, Sendtner M, Melki J, Meininger V, Hardiman O, Andersen PM, Leigh NP, Glass JD, Overste D, Diekstra FP, Veldink JH, van Es MA, Shaw CE, Weale ME, Lewis CM, Williams J, Brown RH, Landers JE, Ticozzi N, Ceroni M, Pegoraro E, Comi GP, D&#x2019;Alfonso S, van den Berg LH, Taroni F, Al-Chalabi A, Powell J, Silani V, SLAGEN Consortium and Collaborators A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis. Human Molecular Genetics. 2014;23:2220&#x2013;2231. doi: 10.1093/hmg/ddt587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt587</ArticleId><ArticleId IdType="pmc">PMC3959809</ArticleId><ArticleId IdType="pubmed">24256812</ArticleId></ArticleIdList></Reference><Reference><Citation>Freed D, Aldana R, Weber JA, Edwards JS. The Sentieon Genomics Tools&#x2014;A Fast and Accurate Solution to Variant Calling from next-Generation Sequence Data. bioRxiv. 2017 doi: 10.1101/115717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/115717</ArticleId></ArticleIdList></Reference><Reference><Citation>Geisler S, Huang SX, Strickland A, Doan RA, Summers DW, Mao X, Park J, DiAntonio A, Milbrandt J. Gene therapy targeting SARM1 blocks pathological axon degeneration in mice. The Journal of Experimental Medicine. 2019;216:294&#x2013;303. doi: 10.1084/jem.20181040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20181040</ArticleId><ArticleId IdType="pmc">PMC6363435</ArticleId><ArticleId IdType="pubmed">30642945</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerdts J, Summers DW, Sasaki Y, DiAntonio A, Milbrandt J. Sarm1-mediated axon degeneration requires both SAM and TIR interactions. The Journal of Neuroscience. 2013;33:13569&#x2013;13580. doi: 10.1523/JNEUROSCI.1197-13.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1197-13.2013</ArticleId><ArticleId IdType="pmc">PMC3742939</ArticleId><ArticleId IdType="pubmed">23946415</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerdts J, Brace EJ, Sasaki Y, DiAntonio A, Milbrandt J. SARM1 activation triggers axon degeneration locally via NAD+destruction. Science. 2015;348:453&#x2013;457. doi: 10.1126/science.1258366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1258366</ArticleId><ArticleId IdType="pmc">PMC4513950</ArticleId><ArticleId IdType="pubmed">25908823</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerdts J, Summers DW, Milbrandt J, DiAntonio A. Axon Self-Destruction: New Links among SARM1, MAPKs, and NAD+ Metabolism. Neuron. 2016;89:449&#x2013;460. doi: 10.1016/j.neuron.2015.12.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.12.023</ArticleId><ArticleId IdType="pmc">PMC4742785</ArticleId><ArticleId IdType="pubmed">26844829</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilley J, Coleman MP. Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons. PLOS Biology. 2010;8:e1000300. doi: 10.1371/journal.pbio.1000300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1000300</ArticleId><ArticleId IdType="pmc">PMC2811159</ArticleId><ArticleId IdType="pubmed">20126265</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilley J, Adalbert R, Yu G, Coleman MP. Rescue of peripheral and CNS axon defects in mice lacking NMNAT2. The Journal of Neuroscience. 2013;33:13410&#x2013;13424. doi: 10.1523/JNEUROSCI.1534-13.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1534-13.2013</ArticleId><ArticleId IdType="pmc">PMC6705152</ArticleId><ArticleId IdType="pubmed">23946398</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilley J, Orsomando G, Nascimento-Ferreira I, Coleman MP. Absence of SARM1 rescues development and survival of NMNAT2-deficient axons. Cell Reports. 2015;10:1974&#x2013;1981. doi: 10.1016/j.celrep.2015.02.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.02.060</ArticleId><ArticleId IdType="pmc">PMC4386025</ArticleId><ArticleId IdType="pubmed">25818290</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilley J, Mayer PR, Yu G, Coleman MP. Low levels of NMNAT2 compromise axon development and survival. Human Molecular Genetics. 2019;28:448&#x2013;458. doi: 10.1093/hmg/ddy356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy356</ArticleId><ArticleId IdType="pubmed">30304512</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilley J, Loreto A. Microinjection of Superior Cervical Ganglion Neurons for Studying Axon Degeneration. Methods in Molecular Biology. 2020;2143:25&#x2013;39. doi: 10.1007/978-1-0716-0585-1_3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-0716-0585-1_3</ArticleId><ArticleId IdType="pubmed">32524470</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez M, Falk MJ, Gai X, Postrel R, Sch&#xfc;le R, Zuchner S. Innovative genomic collaboration using the GENESIS (GEM.app) platform. Human Mutation. 2015;36:950&#x2013;956. doi: 10.1002/humu.22836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22836</ArticleId><ArticleId IdType="pmc">PMC4682547</ArticleId><ArticleId IdType="pubmed">26173844</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA. Diagnosis and Clinical Management of Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. Continuum. 2017;23:1332&#x2013;1359. doi: 10.1212/CON.0000000000000535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/CON.0000000000000535</ArticleId><ArticleId IdType="pubmed">28968365</ArticleId></ArticleIdList></Reference><Reference><Citation>Horsefield S, Burdett H, Zhang X, Manik MK, Shi Y, Chen J, Qi T, Gilley J, Lai JS, Rank MX, Casey LW, Gu W, Ericsson DJ, Foley G, Hughes RO, Bosanac T, von Itzstein M, Rathjen JP, Nanson JD, Boden M, Dry IB, Williams SJ, Staskawicz BJ, Coleman MP, Ve T, Dodds PN, Kobe B. NAD+ cleavage activity by animal and plant TIR domains in cell death pathways. Science. 2019;365:793&#x2013;799. doi: 10.1126/science.aax1911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aax1911</ArticleId><ArticleId IdType="pubmed">31439792</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes RO, Bosanac T, Mao X, Engber TM, DiAntonio A, Milbrandt J, Devraj R, Krauss R. Small Molecule SARM1 Inhibitors Recapitulate the SARM1-/- Phenotype and Allow Recovery of a Metastable Pool of Axons Fated to Degenerate. Cell Reports. 2021;34:108588. doi: 10.1016/j.celrep.2020.108588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108588</ArticleId><ArticleId IdType="pmc">PMC8179325</ArticleId><ArticleId IdType="pubmed">33406435</ArticleId></ArticleIdList></Reference><Reference><Citation>Huppke P, Wegener E, Gilley J, Angeletti C, Kurth I, Drenth JPH, Stadelmann C, Barrantes-Freer A, Br&#xfc;ck W, Thiele H, N&#xfc;rnberg P, G&#xe4;rtner J, Orsomando G, Coleman MP. Homozygous NMNAT2 mutation in sisters with polyneuropathy and erythromelalgia. Experimental Neurology. 2019;320:112958. doi: 10.1016/j.expneurol.2019.112958.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2019.112958</ArticleId><ArticleId IdType="pubmed">31132363</ArticleId></ArticleIdList></Reference><Reference><Citation>Izadifar A, Courchet J, Virga DM, Verreet T, Hamilton S, Ayaz D, Misbaer A, Vandenbogaerde S, Monteiro L, Petrovic M, Sachse S, Yan B, Erfurth ML, Dascenco D, Kise Y, Yan J, Edwards-Faret G, Lewis T, Polleux F, Schmucker D. Axon morphogenesis and maintenance require an evolutionary conserved safeguard function of Wnk kinases antagonizing Sarm and Axed. Neuron. 2021;109:2864&#x2013;2883. doi: 10.1016/j.neuron.2021.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2021.07.006</ArticleId><ArticleId IdType="pubmed">34384519</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Liu T, Lee CH, Chang Q, Yang J, Zhang Z. The NAD+-mediated self-inhibition mechanism of pro-neurodegenerative SARM1. Nature. 2020;588:658&#x2013;663. doi: 10.1038/s41586-020-2862-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2862-z</ArticleId><ArticleId IdType="pubmed">33053563</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, Williams LA, Limone F, Guerra San Juan I, Davis-Dusenbery BN, Mordes DA, Burberry A, Steinbaugh MJ, Gamage KK, Kirchner R, Moccia R, Cassel SH, Chen K, Wainger BJ, Woolf CJ, Eggan K. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nature Neuroscience. 2019;22:167&#x2013;179. doi: 10.1038/s41593-018-0300-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0300-4</ArticleId><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Shin MK, Ryu DK, Kim S, Ryu WS. Insertion and deletion mutagenesis by overlap extension PCR. Methods in Molecular Biology. 2010;634:137&#x2013;146. doi: 10.1007/978-1-60761-652-8_10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-60761-652-8_10</ArticleId><ArticleId IdType="pubmed">20676981</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Emond MJ, Bamshad MJ, Barnes KC, Rieder MJ, Nickerson DA, NHLBI GO Exome Sequencing Project&#x2014;ESP Lung Project Team. Christiani DC, Wurfel MM, Lin X. Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. American Journal of Human Genetics. 2012;91:224&#x2013;237. doi: 10.1016/j.ajhg.2012.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2012.06.007</ArticleId><ArticleId IdType="pmc">PMC3415556</ArticleId><ArticleId IdType="pubmed">22863193</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;26:589&#x2013;595. doi: 10.1093/bioinformatics/btp698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btp698</ArticleId><ArticleId IdType="pmc">PMC2828108</ArticleId><ArticleId IdType="pubmed">20080505</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopate G, Baloh RH, Al-Lozi MT, Miller TM, Fernandes Filho JA, Ni O, Leston A, Florence J, Schierbecker J, Allred P. Familial ALS with extreme phenotypic variability due to the I113T SOD1 mutation. Amyotrophic Lateral Sclerosis. 2010;11:232&#x2013;236. doi: 10.3109/17482960902898069.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960902898069</ArticleId><ArticleId IdType="pubmed">20184521</ArticleId></ArticleIdList></Reference><Reference><Citation>Loreto A, Angeletti C, Gu W, Osborne A, Nieuwenhuis B, Gilley J, Arthur-Farraj P, Merlini E, Amici A, Luo Z, Hartley-Tassell L, Ve T, Desrochers LM, Wang Q, Kobe B, Orsomando G, Coleman MP. Neurotoxin-mediated --potent activation of the axon degeneration regulator SARM1. eLife. 2021;10:e72823. doi: 10.7554/eLife.72823.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.72823</ArticleId><ArticleId IdType="pubmed">34870595</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukacs M, Gilley J, Zhu Y, Orsomando G, Angeletti C, Liu J, Yang X, Park J, Hopkin RJ, Coleman MP, Zhai RG, Stottmann RW. Severe biallelic loss-of-function mutations in nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2) in two fetuses with fetal akinesia deformation sequence. Experimental Neurology. 2019;320:112961. doi: 10.1016/j.expneurol.2019.112961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2019.112961</ArticleId><ArticleId IdType="pmc">PMC6708453</ArticleId><ArticleId IdType="pubmed">31136762</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, Kwong LK, Forman MS, Ravits J, Stewart H, Eisen A, McClusky L, Kretzschmar HA, Monoranu CM, Highley JR, Kirby J, Siddique T, Shaw PJ, Lee VMY, Trojanowski JQ. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Annals of Neurology. 2007;61:427&#x2013;434. doi: 10.1002/ana.21147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21147</ArticleId><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Maekawa S, Leigh PN, King A, Jones E, Steele JC, Bodi I, Shaw CE, Hortobagyi T, Al-Sarraj S. TDP-43 is consistently co-localized with ubiquitinated inclusions in sporadic and Guam amyotrophic lateral sclerosis but not in familial amyotrophic lateral sclerosis with and without SOD1 mutations. Neuropathology&#x202f;. 2009;29:672&#x2013;683. doi: 10.1111/j.1440-1789.2009.01029.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1789.2009.01029.x</ArticleId><ArticleId IdType="pubmed">19496940</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlary L, Plotkin SS, Yerbury JJ, Cashman NR. Prion-Like Propagation of Protein Misfolding and Aggregation in Amyotrophic Lateral Sclerosis. Frontiers in Molecular Neuroscience. 2019;12:262. doi: 10.3389/fnmol.2019.00262.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00262</ArticleId><ArticleId IdType="pmc">PMC6838634</ArticleId><ArticleId IdType="pubmed">31736708</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Research. 2010;20:1297&#x2013;1303. doi: 10.1101/gr.107524.110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.107524.110</ArticleId><ArticleId IdType="pmc">PMC2928508</ArticleId><ArticleId IdType="pubmed">20644199</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z, L&#xf3;pez-Erauskin J, Baughn MW, Zhang O, Drenner K, Sun Y, Freyermuth F, McMahon MA, Beccari MS, Artates JW, Ohkubo T, Rodriguez M, Lin N, Wu D, Bennett CF, Rigo F, Da Cruz S, Ravits J, Lagier-Tourenne C, Cleveland DW. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nature Neuroscience. 2019;22:180&#x2013;190. doi: 10.1038/s41593-018-0293-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0293-z</ArticleId><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Milde S, Adalbert R, Elaman MH, Coleman MP. Axonal transport declines with age in two distinct phases separated by a period of relative stability. Neurobiology of Aging. 2015;36:971&#x2013;981. doi: 10.1016/j.neurobiolaging.2014.09.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.09.018</ArticleId><ArticleId IdType="pmc">PMC4321880</ArticleId><ArticleId IdType="pubmed">25443288</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VMY. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson G, Lenk GM, Reddel SW, Grant AE, Towne CF, Ferguson CJ, Simpson E, Scheuerle A, Yasick M, Hoffman S, Blouin R, Brandt C, Coppola G, Biesecker LG, Batish SD, Meisler MH. Distinctive genetic and clinical features of CMT4J: a severe neuropathy caused by mutations in the PI(3,5)P&#x2082; phosphatase FIG4. Brain&#x202f;: A Journal of Neurology. 2011;134:1959&#x2013;1971. doi: 10.1093/brain/awr148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr148</ArticleId><ArticleId IdType="pmc">PMC3122378</ArticleId><ArticleId IdType="pubmed">21705420</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterloh JM, Yang J, Rooney TM, Fox AN, Adalbert R, Powell EH, Sheehan AE, Avery MA, Hackett R, Logan MA, MacDonald JM, Ziegenfuss JS, Milde S, Hou YJ, Nathan C, Ding A, Brown RH, Conforti L, Coleman M, Tessier-Lavigne M, Z&#xfc;chner S, Freeman MR. dSarm/Sarm1 is required for activation of an injury-induced axon death pathway. Science. 2012;337:481&#x2013;484. doi: 10.1126/science.1223899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1223899</ArticleId><ArticleId IdType="pmc">PMC5225956</ArticleId><ArticleId IdType="pubmed">22678360</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozaki E, Gibbons L, Neto NG, Kenna P, Carty M, Humphries M, Humphries P, Campbell M, Monaghan M, Bowie A, Doyle SL. SARM1 deficiency promotes rod and cone photoreceptor cell survival in a model of retinal degeneration. Life Science Alliance. 2020;3:e201900618. doi: 10.26508/lsa.201900618.</Citation><ArticleIdList><ArticleId IdType="doi">10.26508/lsa.201900618</ArticleId><ArticleId IdType="pmc">PMC7184027</ArticleId><ArticleId IdType="pubmed">32312889</ArticleId></ArticleIdList></Reference><Reference><Citation>Panneerselvam P, Singh LP, Ho B, Chen J, Ding JL. Targeting of pro-apoptotic TLR adaptor SARM to mitochondria: definition of the critical region and residues in the signal sequence. The Biochemical Journal. 2012;442:263&#x2013;271. doi: 10.1042/BJ20111653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20111653</ArticleId><ArticleId IdType="pubmed">22145856</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters OM, Lewis EA, Osterloh JM, Weiss A, Salameh JS, Metterville J, Brown RH, Freeman MR. Loss of Sarm1 does not suppress motor neuron degeneration in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Human Molecular Genetics. 2018;27:3761&#x2013;3771. doi: 10.1093/hmg/ddy260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy260</ArticleId><ArticleId IdType="pmc">PMC6196650</ArticleId><ArticleId IdType="pubmed">30010873</ArticleId></ArticleIdList></Reference><Reference><Citation>Project MinE ALS Sequencing Consortium Project MinE: study design and pilot analyses of a large-scale whole-genome sequencing study in amyotrophic lateral sclerosis. European Journal of Human Genetics. 2018;26:1537&#x2013;1546. doi: 10.1038/s41431-018-0177-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41431-018-0177-4</ArticleId><ArticleId IdType="pmc">PMC6138692</ArticleId><ArticleId IdType="pubmed">29955173</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossor AM, Kalmar B, Greensmith L, Reilly MM. The distal hereditary motor neuropathies. Journal of Neurology, Neurosurgery, and Psychiatry. 2012;83:6&#x2013;14. doi: 10.1136/jnnp-2011-300952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2011-300952</ArticleId><ArticleId IdType="pubmed">22028385</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein J, Berry J, Svendsen C, Thompson L, Finkbeiner S, Van Eyk J, Fraenkel E, Cudkowicz M, Maragakis N, Sareen D, Norel R, Dardov V, Coyne A, Frank A, Matlock A, Pandey R, Vibhav V, Lima L, Wu J, Ramamoorthy D, Lim R, Kaye J, Li J, Thompson T, Baxi E, Answer ALS Answer ALS: A Large-Scale Resource for Sporadic and Familial ALS Combining Clinical Data with Multi-Omics Data from Induced Pluripotent Cell Lines. Research Square. 2020 doi: 10.21203/rs.3.rs-96858/v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-96858/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki Y, Kakita H, Kubota S, Sene A, Lee TJ, Ban N, Dong Z, Lin JB, Boye SL, DiAntonio A, Boye SE, Apte RS, Milbrandt J. SARM1 depletion rescues NMNAT1-dependent photoreceptor cell death and retinal degeneration. eLife. 2020;9:e62027. doi: 10.7554/eLife.62027.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.62027</ArticleId><ArticleId IdType="pmc">PMC7591247</ArticleId><ArticleId IdType="pubmed">33107823</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder CM, Hilke FJ, L&#xf6;ffler MW, Bitzer M, Lenz F, Sturm M. A comprehensive quality control workflow for paired tumor-normal NGS experiments. Bioinformatics. 2017;33:1721&#x2013;1722. doi: 10.1093/bioinformatics/btx032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btx032</ArticleId><ArticleId IdType="pubmed">28130233</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen C, Vohra M, Zhang P, Mao X, Figley MD, Zhu J, Sasaki Y, Wu H, DiAntonio A, Milbrandt J. Multiple domain interfaces mediate SARM1 autoinhibition. PNAS. 2021;118:e2023151118. doi: 10.1073/pnas.2023151118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2023151118</ArticleId><ArticleId IdType="pmc">PMC7848697</ArticleId><ArticleId IdType="pubmed">33468661</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin JE, Miller BR, Babetto E, Cho Y, Sasaki Y, Qayum S, Russler EV, Cavalli V, Milbrandt J, DiAntonio A. SCG10 is a JNK target in the axonal degeneration pathway. PNAS. 2012;109:E3696&#x2013;E3705. doi: 10.1073/pnas.1216204109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1216204109</ArticleId><ArticleId IdType="pmc">PMC3535671</ArticleId><ArticleId IdType="pubmed">23188802</ArticleId></ArticleIdList></Reference><Reference><Citation>Sporny M, Guez-Haddad J, Lebendiker M, Ulisse V, Volf A, Mim C, Isupov MN, Opatowsky Y. Structural Evidence for an Octameric Ring Arrangement of SARM1. Journal of Molecular Biology. 2019;431:3591&#x2013;3605. doi: 10.1016/j.jmb.2019.06.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2019.06.030</ArticleId><ArticleId IdType="pubmed">31278906</ArticleId></ArticleIdList></Reference><Reference><Citation>Sporny M, Guez-Haddad J, Khazma T, Yaron A, Dessau M, Shkolnisky Y, Mim C, Isupov MN, Zalk R, Hons M, Opatowsky Y. Structural basis for SARM1 inhibition and activation under energetic stress. eLife. 2020;9:e62021. doi: 10.7554/eLife.62021.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.62021</ArticleId><ArticleId IdType="pmc">PMC7688312</ArticleId><ArticleId IdType="pubmed">33185189</ArticleId></ArticleIdList></Reference><Reference><Citation>Summers DW, DiAntonio A, Milbrandt J. Mitochondrial dysfunction induces Sarm1-dependent cell death in sensory neurons. The Journal of Neuroscience. 2014;34:9338&#x2013;9350. doi: 10.1523/JNEUROSCI.0877-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0877-14.2014</ArticleId><ArticleId IdType="pmc">PMC4087211</ArticleId><ArticleId IdType="pubmed">25009267</ArticleId></ArticleIdList></Reference><Reference><Citation>Summers DW, Gibson DA, DiAntonio A, Milbrandt J. SARM1-specific motifs in the TIR domain enable NAD+ loss and regulate injury-induced SARM1 activation. PNAS. 2016;113:E6271&#x2013;E6280. doi: 10.1073/pnas.1601506113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1601506113</ArticleId><ArticleId IdType="pmc">PMC5068253</ArticleId><ArticleId IdType="pubmed">27671644</ArticleId></ArticleIdList></Reference><Reference><Citation>Theunissen F, Anderton RS, Mastaglia FL, Flynn LL, Winter SJ, James I, Bedlack R, Hodgetts S, Fletcher S, Wilton SD, Laing NG, MacShane M, Needham M, Saunders A, Mackay-Sim A, Melamed Z, Ravits J, Cleveland DW, Akkari PA. Novel STMN2 Variant Linked to Amyotrophic Lateral Sclerosis Risk and Clinical Phenotype. Frontiers in Aging Neuroscience. 2021;13:658226. doi: 10.3389/fnagi.2021.658226.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2021.658226</ArticleId><ArticleId IdType="pmc">PMC8033025</ArticleId><ArticleId IdType="pubmed">33841129</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P. How much of the missing heritability of ALS is hidden in known ALS genes? Journal of Neurology, Neurosurgery, and Psychiatry. 2018;89:794. doi: 10.1136/jnnp-2018-318354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318354</ArticleId><ArticleId IdType="pmc">PMC6204935</ArticleId><ArticleId IdType="pubmed">29650795</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Spek RAA, van Rheenen W, Pulit SL, Kenna KP, van den Berg LH, Veldink JH, Project MinE ALS Sequencing Consortium&#xb6; The project MinE databrowser: bringing large-scale whole-genome sequencing in ALS to researchers and the public. Amyotrophic Lateral Sclerosis &amp; Frontotemporal Degeneration. 2019;20:432&#x2013;440. doi: 10.1080/21678421.2019.1606244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1606244</ArticleId><ArticleId IdType="pmc">PMC7893599</ArticleId><ArticleId IdType="pubmed">31280677</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, Shatunov A, Dekker AM, McLaughlin RL, Diekstra FP, Pulit SL, van der Spek RAA, V&#xf5;sa U, de Jong S, Robinson MR, Yang J, Fogh I, van Doormaal PT, Tazelaar GHP, Koppers M, Blokhuis AM, Sproviero W, Jones AR, Kenna KP, van Eijk KR, Harschnitz O, Schellevis RD, Brands WJ, Medic J, Menelaou A, Vajda A, Ticozzi N, Lin K, Rogelj B, Vrabec K, Ravnik-Glava&#x10d; M, Koritnik B, Zidar J, Leonardis L, Gro&#x161;elj LD, Millecamps S, Salachas F, Meininger V, de Carvalho M, Pinto S, Mora JS, Rojas-Garc&#xed;a R, Polak M, Chandran S, Colville S, Swingler R, Morrison KE, Shaw PJ, Hardy J, Orrell RW, Pittman A, Sidle K, Fratta P, Malaspina A, Topp S, Petri S, Abdulla S, Drepper C, Sendtner M, Meyer T, Ophoff RA, Staats KA, Wiedau-Pazos M, Lomen-Hoerth C, Van Deerlin VM, Trojanowski JQ, Elman L, McCluskey L, Basak AN, Tunca C, Hamzeiy H, Parman Y, Meitinger T, Lichtner P, Radivojkov-Blagojevic M, Andres CR, Maurel C, Bensimon G, Landwehrmeyer B, Brice A, Payan CAM, Saker-Delye S, D&#xfc;rr A, Wood NW, Tittmann L, Lieb W, Franke A, Rietschel M, Cichon S, N&#xf6;then MM, Amouyel P, Tzourio C, Dartigues J-F, Uitterlinden AG, Rivadeneira F, Estrada K, Hofman A, Curtis C, Blauw HM, van der Kooi AJ, de Visser M, Goris A, Weber M, Shaw CE, Smith BN, Pansarasa O, Cereda C, Del Bo R, Comi GP, D&#x2019;Alfonso S, Bertolin C, Sorar&#xf9; G, Mazzini L, Pensato V, Gellera C, Tiloca C, Ratti A, Calvo A, Moglia C, Brunetti M, Arcuti S, Capozzo R, Zecca C, Lunetta C, Penco S, Riva N, Padovani A, Filosto M, Muller B, Stuit RJ, PARALS Registry. SLALOM Group. SLAP Registry. FALS Sequencing Consortium. SLAGEN Consortium. NNIPPS Study Group. Blair I, Zhang K, McCann EP, Fifita JA, Nicholson GA, Rowe DB, Pamphlett R, Kiernan MC, Grosskreutz J, Witte OW, Ringer T, Prell T, Stubendorff B, Kurth I, H&#xfc;bner CA, Leigh PN, Casale F, Chio A, Beghi E, Pupillo E, Tortelli R, Logroscino G, Powell J, Ludolph AC, Weishaupt JH, Robberecht W, Van Damme P, Franke L, Pers TH, Brown RH, Glass JD, Landers JE, Hardiman O, Andersen PM, Corcia P, Vourc&#x2019;h P, Silani V, Wray NR, Visscher PM, de Bakker PIW, van Es MA, Pasterkamp RJ, Lewis CM, Breen G, Al-Chalabi A, van den Berg LH, Veldink JH. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nature Genetics. 2016;48:1043&#x2013;1048. doi: 10.1038/ng.3622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3622</ArticleId><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan L, Essuman K, Anderson RG, Sasaki Y, Monteiro F, Chung EH, Osborne Nishimura E, DiAntonio A, Milbrandt J, Dangl JL, Nishimura MT. TIR domains of plant immune receptors are NAD+-cleaving enzymes that promote cell death. Science. 2019;365:799&#x2013;803. doi: 10.1126/science.aax1771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aax1771</ArticleId><ArticleId IdType="pmc">PMC7045805</ArticleId><ArticleId IdType="pubmed">31439793</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Research. 2010;38:e164. doi: 10.1093/nar/gkq603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkq603</ArticleId><ArticleId IdType="pmc">PMC2938201</ArticleId><ArticleId IdType="pubmed">20601685</ArticleId></ArticleIdList></Reference><Reference><Citation>White MA, Lin Z, Kim E, Henstridge CM, Pena Altamira E, Hunt CK, Burchill E, Callaghan I, Loreto A, Brown-Wright H, Mead R, Simmons C, Cash D, Coleman MP, Sreedharan J. Sarm1 deletion suppresses TDP-43-linked motor neuron degeneration and cortical spine loss. Acta Neuropathologica Communications. 2019;7:166. doi: 10.1186/s40478-019-0800-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0800-9</ArticleId><ArticleId IdType="pmc">PMC6819591</ArticleId><ArticleId IdType="pubmed">31661035</ArticleId></ArticleIdList></Reference><Reference><Citation>Wragg D, Liu Q, Lin Z, Riggio V, Pugh CA, Beveridge AJ, Brown H, Hume DA, Harris SE, Deary IJ, Tenesa A, Prendergast JGD. Using regulatory variants to detect gene-gene interactions identifies networks of genes linked to cell immortalisation. Nature Communications. 2020;11:343. doi: 10.1038/s41467-019-13762-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-13762-6</ArticleId><ArticleId IdType="pmc">PMC6969137</ArticleId><ArticleId IdType="pubmed">31953380</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T, Zhu J, Strickland A, Ko KW, Sasaki Y, Dingwall C, Yamada Y, Figley MD, Mao X, Neiner A, Bloom J, DiAntonio A, Milbrandt J. Neurotoxins subvert the allosteric activation mechanism of SARM1 to induce neuronal loss. Cell Reports. 2021;37:e109872. doi: 10.1101/2021.07.16.452689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.16.452689</ArticleId><ArticleId IdType="pmc">PMC8638332</ArticleId><ArticleId IdType="pubmed">34686345</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao ZY, Xie XJ, Li WH, Liu J, Chen Z, Zhang B, Li T, Li SL, Lu JG, Zhang L, Zhang LH, Xu Z, Lee HC, Zhao YJ. A Cell-Permeant Mimetic of NMN Activates SARM1 to Produce Cyclic ADP-Ribose and Induce Non-apoptotic Cell Death. IScience. 2019;15:452&#x2013;466. doi: 10.1016/j.isci.2019.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2019.05.001</ArticleId><ArticleId IdType="pmc">PMC6531917</ArticleId><ArticleId IdType="pubmed">31128467</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>